Prime Highlights
- Boehringer Ingelheim has launched a new AI and machine learning centre in London to boost pharmaceutical research.
- The investment strengthens the UK’s position in life sciences and is expected to create skilled jobs.
Key Facts
- Boehringer Ingelheim is a global pharmaceutical company focused on developing innovative medicines.
- The Computational Innovation network now operates across four countries, including the UK and the US.
Background
Boehringer Ingelheim plans to launch a new AI and machine learning hub in King’s Cross, thus joining its existing list of computational innovation centers located around the world.
The opening of the center marks an expansion of the firm’s Computational Innovation centers, which are located across Austria, Germany, the UK, and the US.
The new center will be based in King’s Cross, which is home to a large number of scientific research organizations and universities that specialize in science and technology.
The center will join other research-focused centers in London’s Knowledge Quarter. The London hub will help researchers better understand disease biology, identify effective treatment targets, and improve decision-making in developing new medicines.
Officials stated that the investment will support innovation and create high-skilled jobs. UK Science Minister Patrick Vallance said that artificial intelligence is opening new opportunities in life sciences and that the new centre will contribute to London’s innovation ecosystem while supporting efforts to tackle diseases.
Company leadership also highlighted the UK’s strong foundation in artificial intelligence and healthcare research.
According to their statement, having a presence in London will assist in accessing top talent in the academic and industrial circles, obtaining data, and creating new drugs to address unmet patient needs.
